Results 11 to 20 of about 757 (146)

Effectiveness and Safety of Oral Azvudine for Elderly Hospitalized Patients With COVID‐19: A Multicenter, Retrospective, Real‐World Study [PDF]

Advanced Science
Azvudine is recommended as a priority treatment for patients with Coronavirus Disease 2019 (COVID‐19) during Omicron wave in China, but its efficacy and safety in elderly patients is unknown.
Ranran Sun, Haiyu Wang, Junyi Sun, Mengzhao Yang, Shixi Zhang, Xinjun Hu, Bo Yu, Zhan Song, Na Han, Hong Luo, Ming Cheng, Guangming Li, Guotao Li, Yiqiang Yuan, Lili Liang, Yanyang Zhang, Donghua Zhang, Silin Li, Quancheng Kan, Hongxia Liang, Zhigang Ren   +20 more
doaj   +4 more sources

Effectiveness and safety of azvudine versus nirmatrelvir/ritonavir in hospitalized patients with COVID-19 [PDF]

BMC Infectious Diseases
Purpose To compare the effectiveness and safety of two antiviral drugs, azvudine and nirmatrelvir/ritonavir, in treating hospitalized patients with COVID-19.
Jin Yang, Jiao Min, Ling Ding, Rong Liu, Ya Yang, Jian-feng Zhang, Wei Lei   +6 more
doaj   +5 more sources

Azvudine efficacy in reducing mortality in COVID-19 patients [PDF]

European Journal of Medical Research
Background Several therapeutic drugs have been authorized for the treatment of patients with Coronavirus disease 2019 (COVID-19). However, further research on the mechanisms of action, efficacy, and target populations of these novel therapeutic drugs are
Zhen Zhong, Xiao-feng Liu, Xiao-zhong Zhou, Jia-ning Zhong, Li-cheng Zhou, Rong Li, Xian-fa Liu   +6 more
doaj   +5 more sources

Elevated INR in a COVID-19 patient after concomitant administration of azvudine and anticoagulants [PDF]

Frontiers in Pharmacology, 2023
Background: Azvudine (FNC) is a promising treatment candidate for managing coronavirus disease 2019 (COVID-19). However, drug interactions with azvudine have been poorly studied, especially with no reported cases of azvudine with anticoagulants such as ...
Xi Zhang, Fengwei Jiao, Guangrun Li, Xiaojia Yu, Yuqing Pei, Ying Zhang, Zihui Wang, Zihui Wang, Pengfei Li   +8 more
doaj   +4 more sources

Comparison of Azvudine and Nirmatrelvir/Ritonavir and Combined Use in Patients with COVID-19

Infection and Drug Resistance, 2023
Cheng-Yi Hu,1 Wen-Shuai Cui,1 Yi Lei,1 Yu-Wen Tang,1 Yan-Yan Zhang,1 Qi-Min Su,1 Fang Peng,2 Yun-Fei Zeng,1 Jia-Lin Song,1 Cheng-Na Luo,1 Yan Zhou,1 Xin-Yan Li,1 Zhu-Xiang Zhao1 1Department of Infectious Diseases, Guangzhou First People’s Hospital ...
Hu CY, Cui WS, Lei Y, Tang YW, Zhang YY, Su QM, Peng F, Zeng YF, Song JL, Luo CN, Zhou Y, Li XY, Zhao ZX   +12 more
doaj   +5 more sources

Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study [PDF]

Signal Transduction and Targeted Therapy
Azvudine and nirmatrelvir-ritonavir (Paxlovid) were widely used to treat patients with COVID-19 in China during the Omicron wave. However, the efficacy and safety of azvudine versus Paxlovid are poorly established. This study included 40,876 hospitalized
Haiyu Wang, Guangying Cui, Ming Cheng, Tuerganaili Aji, Guotao Li, Xinjun Hu, Guangming Li, Shixi Zhang, Yanyang Zhang, Linqi Diao, Pan Li, Ling Wang, Yiqiang Yuan, Guowu Qian, Ruiqing Zhang, Xiaoli Jin, Juan Wang, Hong Luo, Donghua Zhang, Mingming Wang, Silin Li, Zhan Song, Mengzhao Yang, Guanyue Su, Ranran Sun, Junbiao Chang, Zujiang Yu, Zhigang Ren   +27 more
doaj   +3 more sources

The Antiviral Efficacy and Safety of Azvudine in Hospitalized SARS‐CoV‐2 Infected Patients with Liver Diseases Based on a Multicenter, Retrospective Cohort Study [PDF]

Advanced Science
Despite azvudine being prioritized for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, its effectiveness and safety remain inadequately substantiated in hospitalized SARS‐CoV‐2 infected patients with liver ...
Junyi Sun, Mengzhao Yang, Guanyue Su, Ling Wang, Xiaobo Hu, Yongjian Zhou, Guangying Cui, Guowu Qian, Yiqiang Yuan, Xinjun Hu, Silin Li, Hong Luo, Shixi Zhang, Guangming Li, Donghua Zhang, Guotao Li, Ming Cheng, Zujiang Yu, Zhigang Ren   +18 more
doaj   +3 more sources

Real-world efficacy and safety of azvudine in hospitalized older patients with COVID-19 during the omicron wave in China: A retrospective cohort study [PDF]

Acta Pharmaceutica Sinica B
Debates persist regarding the efficacy and safety of azvudine, particularly its real-world outcomes. This study involved patients aged ≥60 years who were admitted to 25 hospitals in mainland China with confirmed SARS-CoV-2 infection between December 1 ...
Yuanchao Zhu, Fei Zhao, Yubing Zhu, Xingang Li, Deshi Dong, Bolin Zhu, Jianchun Li, Xin Hu, Zinan Zhao, Wenfeng Xu, Yang Jv, Dandan Wang, Yingming Zheng, Yiwen Dong, Lu Li, Shilei Yang, Zhiyuan Teng, Ling Lu, Jingwei Zhu, Linzhe Du, Yunxin Liu, Lechuan Jia, Qiujv Zhang, Hui Ma, Ana Zhao, Hongliu Jiang, Xin Xu, Jinli Wang, Xuping Qian, Wei Zhang, Tingting Zheng, Chunxia Yang, Xuguang Chen, Kun Liu, Huanhuan Jiang, Dongxiang Qu, Jia Song, Hua Cheng, Wenfang Sun, Hanqiu Zhan, Xiao Li, Yafeng Wang, Aixia Wang, Li Liu, Lihua Yang, Nan Zhang, Shumin Chen, Jingjing Ma, Wei Liu, Xiaoxiang Du, Meiqin Zheng, Liyan Wan, Guangqing Du, Hangmei Liu, Pengfei Jin   +54 more
doaj   +3 more sources

Efficacy and safety of azvudine versus nirmatrelvir/ritonavir in cancer patients with COVID-19 [PDF]

Scientific Reports
Cancer significantly contributes to the unfavorable prognosis of coronavirus disease 2019 (COVID-19) patients. The efficacy and safety of azvudine and nirmatrelvir/ritonavir (Paxlovid) in cancer patients with COVID-19 remain uncertain.
Bohan Jia, Junyi Sun, Di Zhu, Ling Wang, Xiaobo Hu, Haiyu Wang, Guowu Qian, Donghua Zhang, Silin Li, Hong Luo, Shixi Zhang, Guotao Li, Guangming Li, Hongxia Liang, Zujiang Yu, Zhigang Ren   +15 more
doaj   +4 more sources

Real-World Evaluation Study of Azvudine for the Treatment of Patients With COVID-19: A Systematic Review and Meta-Analysis [PDF]

Canadian Journal of Infectious Diseases and Medical Microbiology
Conclusions: Azvudine significantly reduced the hospitalization time and the time to nucleic acid conversion to negative in COVID-19 patients and significantly lowered all-cause mortality (Grading of Recommendations Assessment, Development, and ...
Abiden Kapar, Huling Li, Qian He, Dandan Lin, Dandan Tang, Kai Peng, Yida Wang, Kai Wang   +7 more
doaj   +3 more sources